J&J-Johnson & Johnson (JNJ) Ascends But Remains Behind Market: Some Facts to Note

Company Performance - Johnson & Johnson (JNJ) ended the latest trading session at $145.27, reflecting a +0.55% adjustment from the previous day's close, which lagged behind the S&P 500's gain of 0.73% [1] - Over the past month, JNJ shares have decreased by 6.9%, underperforming the Medical sector's loss of 3.8% and the S&P 500's gain of 0.34% [1] Upcoming Earnings - Johnson & Johnson is scheduled to release its earnings on January 22, 2025, with an expected EPS of$ 2, indicating a 12.66% decline from the same quarter last year [2] - The Zacks Consensus Estimate projects net sales of $22.54 billion, which is a 5.37% increase from the year-ago period [2] Full Year Projections - For the full year, the Zacks Consensus Estimates forecast earnings of$ 9.94 per share and revenue of $88.84 billion, showing changes of +0.2% and -4.49% respectively from the previous year [3] Analyst Estimates - Recent modifications to analyst estimates for Johnson & Johnson are crucial as they reflect near-term business trends, with upward revisions indicating analysts' positive outlook on the company's operations [4] - The Zacks Rank system, which incorporates these estimate changes, provides actionable ratings for investors [5] Zacks Rank and Valuation - Johnson & Johnson currently holds a Zacks Rank of 3 (Hold), with the Zacks Consensus EPS estimate having increased by 0.04% over the last 30 days [6] - The company is trading at a Forward P/E ratio of 14.54, which is a premium compared to the industry average Forward P/E of 13.74 [7] Industry Context - The Large Cap Pharmaceuticals industry, part of the Medical sector, has a Zacks Industry Rank of 131, placing it in the bottom 48% of all industries [8] - Johnson & Johnson has a PEG ratio of 2.49, compared to the industry average PEG ratio of 1.44 [10]